Price to Earnings (P/E)
since 2012
Difficulty: Beginner
Calculation
AbbVie Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net earnings1 (in millions) |
÷ | No. shares of common stock outstanding2 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2012 | 11.51 | = | 38.50 | ÷ | 3.34 | 3.34 | = | 5,275 | ÷ | 1,577,334,090 |
| Dec 31, 2013 | 19.64 | = | 51.04 | ÷ | 2.60 | 2.60 | = | 4,128 | ÷ | 1,588,518,764 |
| Dec 31, 2014 | 55.08 | = | 61.30 | ÷ | 1.11 | 1.11 | = | 1,774 | ÷ | 1,593,886,909 |
| Dec 31, 2015 | 17.01 | = | 54.29 | ÷ | 3.19 | 3.19 | = | 5,144 | ÷ | 1,611,238,226 |
| Dec 31, 2016 | 16.54 | = | 61.77 | ÷ | 3.73 | 3.73 | = | 5,953 | ÷ | 1,593,920,285 |
| Dec 31, 2017 | 35.47 | = | 118.60 | ÷ | 3.34 | 3.34 | = | 5,309 | ÷ | 1,587,972,655 |
1 USD $
2 Data adjusted for splits and stock dividends.
3 Close price on the filing date of AbbVie Inc.'s Annual Report.
Source: Based on data from AbbVie Inc. Annual Reports
Comparison to Competitors
AbbVie Inc., P/E, long-term trends, comparison to competitors
| AbbVie Inc. | Abbott Laboratories | Allergan PLC | Amgen Inc. | Biogen Inc. | Bristol-Myers Squibb Co. | Celgene Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2012 | 11.51 | 9.24 | 111.88 | 15.68 | 26.95 | 30.56 | 28.41 | 14.99 | 25.20 | 19.64 | 20.94 | 13.51 | 21.42 |
| Dec 31, 2013 | 19.64 | 23.25 | – | 18.69 | 38.21 | 35.01 | 46.13 | 13.88 | 42.00 | 18.72 | 37.83 | 9.32 | 77.00 |
| Dec 31, 2014 | 55.08 | 31.30 | – | 22.96 | 31.27 | 49.80 | 49.41 | 33.06 | 12.85 | 17.15 | 13.94 | 23.03 | 118.44 |
| Dec 31, 2015 | 17.01 | 12.83 | 31.94 | 15.95 | 16.67 | 64.22 | 48.59 | 33.35 | 6.75 | 18.80 | 31.64 | 26.37 | 60.50 |
| Dec 31, 2016 | 16.54 | 55.16 | 5.60 | 16.03 | 15.41 | 20.56 | 44.99 | 32.39 | 6.83 | 20.08 | 46.14 | 28.10 | 42.64 |
| Dec 31, 2017 | 35.47 | 220.29 | – | 64.06 | 28.83 | 103.55 | 24.35 | – | 22.75 | 268.10 | 61.63 | 9.99 | 28.99 |
Source: Based on data from AbbVie Inc. Annual Reports
Comparison to Pharmaceuticals & Biotechnology Sector
AbbVie Inc., P/E, long-term trends, comparison to Pharmaceuticals & Biotechnology sector
| AbbVie Inc. | Pharmaceuticals & Biotechnology | |
|---|---|---|
| Dec 31, 2012 | 11.51 | 17.06 |
| Dec 31, 2013 | 19.64 | 20.82 |
| Dec 31, 2014 | 55.08 | 23.76 |
| Dec 31, 2015 | 17.01 | 19.56 |
| Dec 31, 2016 | 16.54 | 18.35 |
| Dec 31, 2017 | 35.47 | 40.95 |
Source: Based on data from AbbVie Inc. Annual Reports
Comparison to Health Care Industry
AbbVie Inc., P/E, long-term trends, comparison to Health Care industry
| AbbVie Inc. | Health Care | |
|---|---|---|
| Dec 31, 2012 | 11.51 | 16.69 |
| Dec 31, 2013 | 19.64 | 20.65 |
| Dec 31, 2014 | 55.08 | 23.84 |
| Dec 31, 2015 | 17.01 | 20.31 |
| Dec 31, 2016 | 16.54 | 19.29 |
| Dec 31, 2017 | 35.47 | 34.72 |
Source: Based on data from AbbVie Inc. Annual Reports